BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 14, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld, Analysis and data insight

BioWorld, Analysis and data insight
BioWorld, Analysis and data insight RSS Feed RSS

BioWorld and Nasdaq stock indices

Jan. 5, 2024
These graphs compare the performance of the biotech stocks for all of 2023 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More

Biopharma money raised: Jan. 1-Dec. 29, 2023

Jan. 5, 2024
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Biopharma money raised by quarter in 2023 (US$M)

Jan. 5, 2024
Biopharma money raised to-date and by month in 2023, including public, private and other financings.
Read More

Money raised by biopharma

Jan. 5, 2024

Total raised in public, private and other financings of biopharma companies, comparing 2019-2023.


Read More

Biggest gainers and losers for Dec. 25-29, 2023

Jan. 2, 2024
The top 10 biopharma stock gainers and losers for the week.
Read More
Clinical data illustration
Biopharma clinical updates November 2023

BioWorld reports on 3,000+ clinical trial updates through November

Dec. 29, 2023
By Amanda Lanier
Clinical trial updates saw a 5.82% increase for the period of January to November 2023 compared to the same period last year. In November, BioWorld reported on 354 phase I-III trial updates. Although marking a decline from the 416 reported in October, the number of updates still surpasses the previous three months.
Read More

Biopharma money raised: Jan. 1-Dec. 27, 2023

Dec. 29, 2023
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma

Dec. 29, 2023

Total raised in public, private and other financings of biopharma companies, comparing 2019-2023.


Read More

Biggest gainers and losers for Dec. 18-22, 2023

Dec. 27, 2023
The top 10 biopharma stock gainers and losers for the week.
Read More
FDA Approved stamp
Biopharma regulatory actions and approvals November 2023

FDA nods remain up from last year, yet lag behind 2017-2021

Dec. 22, 2023
By Amanda Lanier
In November, the U.S. FDA approved a total of 12 drugs, a decrease from 27 the previous month that marked the highest number of approvals since June 2020, as reported by BioWorld. From January to November, FDA approvals reached 167, an increase of 21.9% from 137 drugs approved during the same time period the previous year.
Read More
Previous 1 2 … 95 96 97 98 99 100 101 102 103 … 242 243 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • Purple molecules

    Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

    BioWorld
    Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • 3D illustration of a nerve cell

    Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

    BioWorld
    Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
  • Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists

    BioWorld Science
    Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing